@article{820b547f68b444769f5a07eaa3d1b4fe,
title = "The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy",
keywords = "acute myeloid leukemia, breast cancer, dendritic cell migration, dendritic cell vaccination, glioblastoma, melanoma, mutational load, neoantigens, ovarian cancer, pancreatic cancer",
author = "Cannon, {Martin J.} and Block, {Matthew S.} and Morehead, {Lauren C.} and Knutson, {Keith L.}",
note = "Funding Information: The authors are supported in part by the grants from the NIH (Mayo Clinic Ovarian Cancer SPORE, P50 CA136393: MJ Cannon, MS Block, KL Knutson), the Department of Defense Ovarian Cancer Research Program (OC160385: MJ Cannon) and Tapimmune, Inc. (MS Block, KL Knutson). MJ Cannon and the University of Arkansas for Medical Sciences (UAMS) have a financial interest in the technologies discussed in this publication. These financial interests have been reviewed and approved in accordance with UAMS conflict of interest policies. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.",
year = "2019",
month = feb,
doi = "10.2217/imt-2018-0129",
language = "English (US)",
volume = "11",
pages = "75--79",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "2",
}